Doravirine/lamivudine/tenofovir disoproxil fumarate

Drug Profile

Doravirine/lamivudine/tenofovir disoproxil fumarate

Alternative Names: MK-1439/lamivudine/tenofovir disoproxil fumarate; MK-1439A

Latest Information Update: 23 Mar 2016

Price : $50

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Nitriles; Phosphonic acids; Purines; Pyridones; Pyrimidine nucleosides; Small molecules; Triazoles
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV-1 infections

Most Recent Events

  • 01 Mar 2016 Phase-II clinical trials in HIV-1 infections in United Kingdom (PO)
  • 01 Feb 2016 Merck plans a phase-II trial for HIV-1 infections in United Kingdom (NCT02652260)
  • 01 Jan 2016 Phase-II clinical trials in HIV-1 infections (Treatment-naive) in Canada (PO) (NCT02629822)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top